Acute Care Events During Systemic Cancer Treatment: Moving From Risk Prediction to Clinical Decision Support Using a Two-Model Approach
- 26 March 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500950
Abstract
PURPOSE: Acute care events (ACEs, emergency department visits and hospitalizations) are burdensome among patients with cancer—many are preventable. Prognostic risk models have not been consistently deployed as a preventive strategy. We convened a Clinical Advisory Panel (CAP) to address this translational bottleneck and develop clinically and statistically valid prognostic models to enable risk-stratified intervention. METHODS: We identified patients age 21+ years initiating cancer treatment at an academic center or affiliated sites. We extracted sociodemographic and clinical information from the EHR. Data were divided into training (50%), validation (25%), and test (25%) sets. Models were developed using constrained elastic-net logistic regression, with clinically informed coefficient constraints. RESULTS: In all, 4,697 patients were included, the mean age was 64 years, 71.9% were White, 21.8% had GI cancers, 21.7% had hematologic malignancies, 46.0% were Medicare insured, 77.6% were receiving chemotherapy, and 25.4% were receiving immunotherapy. We developed two models with our CAP, a baseline model predicting risk using a planned anticancer regimen and a follow-up model updating with drug dispensing and clinical changes. ACE in the previous month was the strongest predictor in both models (odds ratio [OR], 1.5, baseline model), with chemotherapy receipt (OR, 1.18), heart failure (OR, 1.22), abnormal international normalized ratio (OR, 1.30), and late-stage cancer (OR, 1.20) contributing. Both had acceptable statistical performance (C-statistic 0.71 and 0.70) and identified patients at the highest risk for ACE. CONCLUSION: We present a novel approach to ACE prediction among patients receiving cancer treatment using two models to anticipate patients' risk before treatment starts and then update based on clinical trajectory, facilitated by engagement of a CAP. To prevent ACE, risk-stratified interventions should focus on the factors we observed—optimizing comorbidities, proactively managing symptoms from high-toxicity regimens, or advanced disease.Keywords
This publication has 21 references indexed in Scilit:
- TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methodsBMJ, 2024
- Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer SurgeryJournal of Clinical Oncology, 2022
- Machine Learning Applied to Electronic Health Records: Identification of Chemotherapy Patients at High Risk for Preventable Emergency Department Visits and Hospital AdmissionsJCO Clinical Cancer Informatics, 2021
- Building a Clinically Relevant Risk Model: Predicting Risk of a Potentially Preventable Acute Care Visit for Patients Starting Antineoplastic TreatmentJCO Clinical Cancer Informatics, 2020
- A Multi-faceted Intervention Aimed at Black-White Disparities in the Treatment of Early Stage Cancers: The ACCURE Pragmatic Quality Improvement trialJournal of the National Medical Association, 2020
- Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World DataJCO Clinical Cancer Informatics, 2019
- Development and Validation of a Score to Predict Acute Care Use After Initiation of Systemic Therapy for CancerJAMA Network Open, 2019
- Can Patient Navigation Improve Receipt of Recommended Breast Cancer Care? Evidence From the National Patient Navigation Research ProgramJournal of Clinical Oncology, 2014
- Impact of Patient Navigation on Timely Cancer Care: The Patient Navigation Research ProgramJNCI: Journal of the National Cancer Institute, 2014
- Development of a comorbidity index using physician claims dataJournal of Clinical Epidemiology, 2000